ORIGINAL RESEARCH article

Front. Immunol.

Sec. Cancer Immunity and Immunotherapy

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1618487

This article is part of the Research TopicPANoptosis and its role in T cell-based immunotherapyView all 5 articles

Prognostic and Immunological Implications of Cathepsin Z Overexpression in Prostate Cancer

Provisionally accepted
Junyue  TaoJunyue Tao1Yiding  ChenYiding Chen1Xiaokang  BianXiaokang Bian1Tingting  CaiTingting Cai2Changhao  SongChanghao Song1Chaozhao  LiangChaozhao Liang1Zongyao  HaoZongyao Hao1Jialing  MengJialing Meng1Qingtao  GeQingtao Ge2*Jun  ZhouJun Zhou1*
  • 1Department of Urology, First Affiliated Hospital of Anhui Medical University, Hefei, China
  • 2Shanghai Cancer Center, Fudan University, Shanghai, Shanghai Municipality, China

The final, formatted version of the article will be published soon.

Recent studies have underscored the potential involvement of cathepsin Z (CTSZ) in modulating the progression of diverse tumor types. Nevertheless, its specific role in prostate cancer (PCa) remains insufficiently understood. This study aimed to investigate the expression profile of CTSZ in PCa and evaluate its prognostic significance.Methods: Three independent cohorts, including TCGA-PRAD, MSKCC, and a real-world AHMU-PC cohort were enrolled in this study. Multidimensional strategies consist of spatial transcriptome analysis, differential expression analysis, survival analysis, and correlation with clinicopathological features were performed. Immunohistochemical staining and multiplex immunofluorescence staining were performed to evaluate the expression and spatial distribution of CTSZ and immune-related markers in PCa tissues. Functional studies were conducted through a series of experiments, including CCK-8 assay, colony formation, wound healing, and Transwell migration assays. ssGSEA and CIBERSORT algorithms immune infiltration evaluation, and GISTIC2.0 and MutSigCV for tumor mutation burden. Gene Set Enrichment Analysis was performed to identify potential signaling pathways involved.Results: CTSZ is highly expressed in PCa tissues and is associated with higher Gleason scores, advanced T/N staging, and poor prognosis. Survival analyses across multiple cohorts indicate that high CTSZ expression predicts shorter progression-free survival and overall survival. In vitro experiments showed that CTSZ knockdown suppresses PCa cell proliferation, invasion, migration, and colony formation. Immune profiling revealed that high-CTSZ tumors exhibit an immuneenriched microenvironment, characterized by increased infiltration of regulatory T cells and M2 macrophages, suggesting an immunosuppressive state. Notably, despite this phenotype, PD-1 and PD-L1 levels were also elevated in high-CTSZ tumors, indicating a potential role in immune checkpoint regulation. Additionally, high CTSZ expression was correlated with increased tumor mutation burden, particularly enriched for TP53 and SPOP mutations. GSEA identified CAM, VEGF, and STAT signaling pathways as potential mechanisms through which CTSZ promotes tumor progression, highlighting its potential as both a prognostic biomarker and therapeutic target in PCa.These findings suggest that CTSZ may serve not only as a predictor of patient prognosis but also as a promising indicator for immunotherapy response and personalized treatment strategies in PCa.

Keywords: Cathepsin Z, prostate cancer, expression profile, prognosis, Immune infiltration, Immune checkpoint, Tumor mutation burden

Received: 26 Apr 2025; Accepted: 28 May 2025.

Copyright: © 2025 Tao, Chen, Bian, Cai, Song, Liang, Hao, Meng, Ge and Zhou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Qingtao Ge, Shanghai Cancer Center, Fudan University, Shanghai, 200032, Shanghai Municipality, China
Jun Zhou, Department of Urology, First Affiliated Hospital of Anhui Medical University, Hefei, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.